Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18

International Immunology

Volumn 17, Issue 2, 2005, Pages 167-176

  Smith, Kelly L ^a   Tristram, Amanda ^a   Gallagher, Kathleen M ^a   Fiander, Alison N ^a   Man, Stephen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

ELISPOT; Papillomavirus; Vaccinia virus

Indexed keywords

EPITOPE; GAMMA INTERFERON; SMALLPOX VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HLA TYPING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS INFECTION;

ADULT; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; DNA-BINDING PROTEINS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PEPTIDES; UTERINE CERVICAL DYSPLASIA; VACCINES, SYNTHETIC; VIRAL VACCINES; VULVAR NEOPLASMS;

EID: 13844250641     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh197     Document Type: Article

References (50)

1. Frazer, I. H. 2004. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev. Immunol. 4:46.
2. Koutsky, L. A., Ault, K. A., Wheeler, C. M. et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645.
3. Cannistra, S. A. and Niloff, J. M. 1996. Cancer of the uterine cervix. N. Engl. J. Med. 334:1030.
4. Fiander, A. and Man, S. 2002. Anti-viral vaccination for treating intraepithelial neoplasia. In Maclean, A., Singer, A. and Critchley, H., eds, Lower Genital Tract Neoplasia, p. 192. Royal College of Obstetricians and Gynaecologists, London.
5. Kono, K., Ressing, M. E., Brandt, R. M. P. et al. 1996. Decreased expression of signal transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res. 2:1825.
6. Brady, C. S., Bartholomew, J. S., Burt, D. J. et al. 2000. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55:401.
7. Youde, S. J., Dunbar, P. R., Evans, E. M. et al. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201 /HPV16E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res. 60:365.
8. Evans, M., Borysiewicz, L. K., Evans, A. S. et al. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167:5420.
9. Ressing, M. E. et al. 1995. Human ctl epitopes encoded by human papillomavirus type 16 e6 and e7 identified through in vivo and in vitro immunogenicity studies of HLA-A *0201 binding peptides. J. Immunol. 154:5934.
10. Kjaer, S. K. et al. 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Br. Med. J. 325:572.
11. Ho, G. Y. F., Bierman, R., Beardsley, L., Chang, C. J. and Burk, R. D. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:423.
12. Jacobs, M. V., de Roda Husman, A. M., van den Brule, A. J., Snijders, P. J., Meijer, C. J. and Walboomers, J. M. 1995. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J. Clin. Microbiol. 33:901.
13. Borysiewicz, L. K. et al. 1996. A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18, e6 and e7 proteins as immunotherapy for cervical cancer. Lancet 347:1523.
14. van der Burg, S. et al. 2001. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16 positive cervical lesions: identification of three human leukocyte antigen class II restricted epitopes. Int. J. Cancer 91:612.
15. Khanna, R., Burrows, S. R., Steigerwald-Mullen, P. M., Moss, D. J., Kurilla, M. G. and Cooper, L. 1997. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int. Immunol. 9:1537.
16. Rickinson, A. B. and Moss, D. J. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Ann. Rev. Immunol. 15:405.
17. Gotch, F. M., Rothbard, J. B., Howland, K., Townsend, A. R. M. and McMichael, A. J. 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326:881.
18. Wills, M. R. et al. 1996. The human cytotoxic T lymphocyte (ctl) response to cytomegalovirus is dominated by structural protein pp65 frequency, specificity, and T cell receptor usage of pp65 specific ctl. J. Virol. 70:7569.
19. Gelder, C. M., Welsh, K. I., Faith, A., Lamb, J. R. and Askonas, B. A. 1995. Human cd4(+) T cell repertoire of responses to influenza a virus hemagglutinin after recent natural infection. J. Virol. 69:7497.
20. DiBrino, M., Tsuchida, T., Turner, R. V., Parker, K. C., Coligan, J. E. and Biddison, W. E. 1993. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J. Immunol. 151:5930.
21. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J. Immunol. 19:2237.
22. Currier, J. R. et al. 2002. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260:157.
23. Adams, M. et al. 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19:2549.
24. Welters, M. J. et al. 2003. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63:636.
25. Kern, F. et al. 2000. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 30:1676.
26. Draenert, R. et al. 2003. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J. Immunol. Methods 275:19.
27. Goon, P. K. et al. 2003. High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease. J. Virol. 77:9716.
28. Valmori, D. et al. 1999. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res. 59:4050.
29. Karanikas, V. et al. 2003. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J. Immunol. 171:4898.
30. Stanley, M. A. 1994. Replication of human papillomaviruses in cell culture. Antivir. Res. 24:1.
31. Tindle, R. W. 2002. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev. Cancer 2:59.
32. de Jong, A. et al. 2002. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 62:472.
33. Reece, W. H. et al. 2004. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10:406.
34. Luxton, J. C., Rowe, A. J., Cridland, J. C., Coletart, T., Wilson, P. and Shepherd, P. S. 1996. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J. Gen. Virol. 77:1585.
35. Kadish, A. S. et al. 1997. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and ET outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89:1285.
36. de Gruijl, T. D. et al. 1996. T-cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. Gen. Virol. 77:2183.
37. Evans, E. M., Man, S., Evans, A. S. and Borysiewicz, L. K. 1997. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57:2943.
38. Williams, O. M., Hart, K. W., Wang, E. C. and Gelder, C. M. 2002. Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J. Virol. 76:7418.
39. Munoz, N. et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518.
40. Woodman, C. B. et al. 2003. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 361:40.
41. Nilges, K. et al. 2003. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J. Virol. 77:5464.
42. Fernando, G. J. P., Tindle, R. W. and Frazer, R. W. 1995. T-helper epitopes of the E7 transforming protein of cervical-cancer associated human papillomavirus type-18 (Hpv18). Virus Res. 36:1.
43. Thurner, B. et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
44. Tan, L. C. et al. 1999. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827.
45. Khammanivong, V. et al. 2003. Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol. Cell Biol. 81:1.
46. Zwaveling, S. et al. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:350.
47. Smyth, L. J. et al. 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res. 10:2954.
48. Baldwin, P. J. et al. 2003. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. 9:5205.
49. Davidson, E. J. et al. 2003. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 63:6032.
50. Christensen, N. D., Han, R., Cladel, N. M. and Pickel, M. D. 2001. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob. Agents Chemother. 45:1201.